LTA4H-Targeted Drug Discovery Services

Introduction

Leukotriene A4 hydrolase (LTA4H) is a bifunctional zinc metallo-enzyme that is encoded by the LTA4H gene in humans. The protein encoded by this gene is an enzyme that contains both hydrolase and aminopeptidase activities. The hydrolase activity is used in the final step of the biosynthesis of leukotriene B4, a pro-inflammatory mediator. The aminopeptidase activity has been shown to degrade proline-glycine-proline (PGP), a neutrophil chemoattractant and biomarker for chronic obstructive pulmonary disease (COPD). Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2015] Related studies indicated that LTA4H is a key factor to regulate the cell cycle at the G0 / G1 phase acting by negatively regulating p27 expression in skin cancer. In the LTA4H-knock-out mouse model, it has been verified that the development of skin cancer was inhibited. Studies in vitro have shown similar results. Therefore, LTA4H is a potential target to prevent and/or treat cancer.

Direction of Drugs Discovery

• LTA4H Inhibitor
• Developing New Clinical Effects on LTA4H from Existing Drugs

Drugs

• LTA4H Inhibitor- Bestatin, DG051, JNJ-10392980, SA-6541

What We Offer

Target Testing

CD BioSciences provides LTA4H testing services by ELISA, Flow, WB, IP, IF, ICC, or IHC assay. The results of LTA4H testing are used to evaluate the activities of candidates against LTA4H or targeted diseases. You can choose one or more testing ways to detect the level of LTA4H according to your experiment.

Hit Identification (show more)

The goal of early drug discovery is to find novel lead compounds that have the desired potency, selectivity, and ADMET properties for pre-clinical evaluation.
CD BioSciences offers hit identification services to make your finding of targeted compounds more successful and faster.
• High-Throughput Screening
• LTA4H-Targeted in Silico Virtual Screening
• Fragment-Based Screening
• High-Content Screening

Antibody Drugs Development Services (show more)

Antibody drugs exhibit many incomparable advantages, such as high specificity, affinity, and efficiency, which is an emerging direction on targeted drug development. CD BioSciences provides comprehensive services on LTA4H-targeted antibody drugs development with professional technology, extensive experience, and advanced equipment.
• Antibody Preparation Services
• Phage Display Services
• Antibody-Drug Conjugates
• Bispecific Antibody Services
• Antibody Humanization Services

Pharmacological Experiments (show more)

We will create a specific experimental plan according to your requirements, including but not limited to
• Pharmacokinetics / Pharmacodynamics
• Pharmacodynamics
• Pharmacokinetics
• Safety Pharmacology

Disease Models Screening (show more)

We will create specific disease models to accelerate your targeted drug discovery project, including but not limited to
• Diseases—Tuberculous meningitis, intestinal tuberculosis, etc.
CD BioSciences will establish the specific disease models according to your requirements to evaluate the inhibitory activity of your candidates targeted LTA4H. We have various cell lines and the species of our animal models cover rats, mice, rabbits, dogs, and non-human primates.

Inquire Us

References

1. Stelzer G.; et al. The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analysis, Current Protocols in Bioinformatics (2016), 54:1.30.1 - 1.30.33.doi: 10.1002 / cpbi.5.
2. Wishart DS; et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue): D901-6.
3. Y. Zhou; et al. Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents. Nucleic Acids Research. 50(D1): 1398-1407 (2022). PMID: 34718904.
4. Oi, N., et al., Lta4h regulates cell cycle and skin carcinogenesis. Carcinogenesis, 2017. 38(7): p. 728-737.